chufangao/CTO huggingface dataset:
Clinical trial NCT04391309: COVID-19 and Anti-CD14 Treatment Trial
Official title: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Hospitalized Patients With COVID-19
Acronym: CaTT
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Stopped to slow rate of enrollment
Enrollment: 49.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-12
Primary completion date: 2022-02-04
Completion date: 2022-02-04
Baseline population: Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product. Measures reflect the assessment of clinical status at baseline.
Limitations and caveats: The trial was terminated early because of slow recruitment and cannot be considered fully powered.
Plan to share individual participant data: NO
Clinical trial NCT04395339: GM1 Prophylaxis for WBRT Related Cognitive Dysfunction
Official title: Ganglioside-Monosialic Acid Prophylaxis for Cognitive Dysfunction Related to Whole Brain Radiotherapy in Breast Cancer Patients With Brain Metastases ，a Multi-center，Randomized，Single Blind，Phase III Clinical Trail
Acronym: GLORY
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Difficulty accruing subjects the study accrual was closed
Enrollment: 51.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-15
Primary completion date: 2024-07-31
Completion date: 2024-07-31
Plan to share individual participant data: NO
Clinical trial NCT03760965: Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Chinese Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Diet and Exercise
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sanofi ended collaboration with Lexicon for Sotagliflozin. In China no regulatory pathway to transfer sponsorship during the conduct of ongoing studies.
Enrollment: 276.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-27
Primary completion date: 2020-04-24
Completion date: 2020-04-24
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04354714: Ruxolitinib to Combat COVID-19
Official title: A Pilot Study of Ruxolitinib to Combat COVID-19
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Could not make FDA required changes
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-30
Primary completion date: 2021-07-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT02551991: Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Official title: A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Sponsor: Ipsen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 56.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-10-19
Primary completion date: 2021-02-15
Completion date: 2021-02-15
Baseline population: Safety population included participants who received at least 1 dose of any study treatment.
Limitations and caveats: The comparative Part 2 was removed in a protocol amendment, dated 11 April 2018, before it was initiated, as this comparative part of the study is being undertaken as a stand-alone Phase 3 study D-US-60010-001.
Clinical trial NCT03863288: Dose Response Relationship of Oxytocin on Irritability in Youths
Official title: Dose-Response Relationship and Pharmacokinetics of Intranasal Oxytocin on Neural Impact in Youth With High Levels of Irritability
Sponsor: University of Nebraska (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Per DSMB's recommendation
Enrollment: 60.0 (ACTUAL)
Number of arms: 5.0
Start date: 2022-02-18
Primary completion date: 2024-02-27
Completion date: 2024-02-27
Clinical trial NCT03087513: A Randomized Controlled Crossover Study Comparing Sugammadex and Placebo
Official title: Effect of Reversal of Neuromuscular Blockade on the Amplitude of Motor Evoked Potentials: A Randomized Controlled Crossover Study Comparing Sugammadex and Placebo
Sponsor: University Health Network, Toronto (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-05
Primary completion date: 2019-12-30
Completion date: 2020-04-30
Plan to share individual participant data: NO
Clinical trial NCT01202994: Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
Official title: Practice Effects and Amyloid Imaging Using 18F-PIB (18F-39-F-6-OH-BTA1) Known as [18FGE067]) or Flutemetamol PET and FDG-PET
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 27.0 (ACTUAL)
Number of arms: 1.0
Start date: 2011-05-31
Primary completion date: 2016-05-31
Completion date: 2020-10-14
Plan to share individual participant data: NO
Clinical trial NCT03084536: PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
Official title: PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 134.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-07
Primary completion date: 2021-02-25
Completion date: 2021-02-25
Plan to share individual participant data: NO
Clinical trial NCT04417894: A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 133.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-14
Primary completion date: 2022-08-31
Completion date: 2022-11-23
Plan to share individual participant data: YES
IPD sharing description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
IPD access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Clinical trial NCT03043053: The Effects of Oxytocin in Obese Adults
Official title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Repeat Doses of Intranasal Oxytocin in Obese Adults
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 61.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-01
Primary completion date: 2022-05-20
Completion date: 2022-07-07
Baseline population: Safety cohort, which was defined as all randomly assigned participants who received at least one dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT03881995: Effects of Insulin Glargine and Lixisenatide on the Brain
Official title: Effect of Insulin Glargine and Lixisenatide Versus Insulin Glargine on Brain Insulin Sensitivity in Patients With Type 2 Diabetes
Acronym: Lixibrain01
Sponsor: University Hospital Tuebingen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: insufficient recruitment
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-18
Primary completion date: 2020-06-29
Completion date: 2020-06-29
Plan to share individual participant data: NO
Clinical trial NCT04025216: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Official title: A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The sponsor finds the risk/benefit analysis unfavorable and has terminated the study.
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-10
Primary completion date: 2022-12-02
Completion date: 2022-12-02
Plan to share individual participant data: NO
Clinical trial NCT05015972: UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies
Official title: A Study of CTA30X UCAR-T Cell Injection in the Treatment of Patients With r/r CD19+ B Hematologic Malignancies
Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: No proper participant is found.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-20
Primary completion date: 2023-06-30
Completion date: 2023-12-31
Clinical trial NCT03193346: BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine
Official title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine
Sponsor: Allergan (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Corporation Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-03
Primary completion date: 2021-03-25
Completion date: 2021-03-25
Clinical trial NCT03577730: Caffeine and Neurologic Recovery Following Surgery and General Anesthesia
Official title: Caffeine and Neurologic Recovery Following Surgery and General Anesthesia
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 71.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-10
Primary completion date: 2019-11-21
Completion date: 2020-01-17
Plan to share individual participant data: NO
Clinical trial NCT03580967: Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes
Official title: Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes: Role of Inflammation, Kynurenine Pathway, and Structural and Functional Brain Connectivity as Biomarkers
Sponsor: Loyola University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: COVID-19 Pandemic interfered with Pt recruitment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-01
Primary completion date: 2021-07-01
Completion date: 2021-07-01
Plan to share individual participant data: NO
Clinical trial NCT03047473: Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
Official title: Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
Acronym: SEJ
Sponsor: Clinique Neuro-Outaouais (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-03-10
Primary completion date: 2021-08-09
Completion date: 2021-08-09
Clinical trial NCT03771885: BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)
Official title: A Phase Ib, Multicentre, Randomised, Double-blind, Placebo Controlled, 8 Week Crossover Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered BI 705564 in Patients With Systemic Lupus Erythematosus.
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Based on a strategic decision, the application for the trial has been withdrawn before initiation.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-16
Primary completion date: 2019-12-21
Completion date: 2020-01-07
Plan to share individual participant data: NO
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:~1. studies in products where Boehringer Ingelheim is not the license holder;~2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;~3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).~For more details refer to: https://www.mystudywindow.com/msw/datasharing
Clinical trial NCT02341209: Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma
Official title: Doxycycline in Patients With Relapsed Cutaneous T-cell Lymphoma
Acronym: CTCL
Sponsor: Rochester General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low enrollment
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-02-06
Primary completion date: 2021-02-06
Completion date: 2021-02-06
Plan to share individual participant data: YES
IPD sharing description: As required
Clinical trial NCT02155634: Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Official title: Phase 3b, Randomized Trial of Continuous Revlimid® (Lenalidomide) Therapy Versus Observation Following Induction Therapy That Does Not Include Revlimid, Pomalyst® or Thalomid® in Newly Diagnosed Multiple Myeloma
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The study was terminated due to poor feasibility and lack of interest at the participating sites.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-07-31
Primary completion date: 2017-04-30
Completion date: 2021-03-31
Clinical trial NCT03582384: Use of Tocofersolan (Vedrop®) to Prevent or Treat Refractive Vitamin E Deficiency in Infants and Children
Official title: Use of Tocofersolan (Vedrop®) to Prevent or Treat Refractive Vitamin E Deficiency in Infants and Children
Sponsor: Boston Children's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study never started
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-31
Primary completion date: 2022-01-31
Completion date: 2023-01-31
Plan to share individual participant data: NO
Clinical trial NCT04030572: Feasibility of Administering Clonidine as a Pharmacological Challenge in Imaging Studies
Official title: Pilot Study to Assess the Safety, Tolerability, and Feasibility of Administering Clonidine as a Pharmacological Challenge in Future Imaging Studies of Cerebrospinal Fluid Kinetics
Acronym: a2a Agonist
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Not logistically feasible during the COVID pandemic
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-10
Primary completion date: 2020-03-17
Completion date: 2020-03-17
Plan to share individual participant data: YES
IPD sharing description: All de-identified on-study data will be shared.
IPD time frame: Data will be made available within six months of last study visit or acceptance for publication, whichever comes first.
IPD access criteria: Any reasonable request sent to dvm9029@med.cornell.edu
Clinical trial NCT01100502: A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant
Sponsor: Seagen Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 329.0 (ACTUAL)
Number of arms: 2.0
Start date: 2010-04-30
Primary completion date: 2014-08-31
Completion date: 2020-04-27
Baseline population: Intention-to-Treat analysis set
Clinical trial NCT03815916: 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease
Official title: A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Parkinson's Disease
Acronym: REPAIR-PD
Sponsor: Clene Nanomedicine (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 13.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-12-19
Primary completion date: 2021-06-07
Completion date: 2021-06-07
Baseline population: Intent to Treat Population (ITT):~The Intent to Treat population consisted of all screened subjects who were assigned a treatment assignment number.
Limitations and caveats: Only 13 participants were enrolled due to difficulties with recruitment that was further complicated by the COVID-19 pandemic.
Plan to share individual participant data: NO
Clinical trial NCT04759131: Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A
Official title: A Phase 3 Open-label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A
Acronym: XTEND-Kids
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 74.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-19
Primary completion date: 2023-01-18
Completion date: 2023-01-18
Baseline population: Analysis was performed on full analysis set (FAS) which included all participants who took at least 1 dose of study intervention.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03841565: Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Official title: Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Sponsor: Academic and Community Cancer Research United (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: There are no patients enrolled on this study and all efforts are being discontinued.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-07
Primary completion date: 2022-02-09
Completion date: 2022-02-09
Clinical trial NCT04566601: A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder
Official title: A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 1358894 Once Daily Over 12 Week Treatment Period in Patients With Borderline Personality Disorder
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 390.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-11-13
Primary completion date: 2022-12-09
Completion date: 2023-01-25
Baseline population: Treated Set (TS) consisted of all patients who were randomised and that received at least one administration of trial medication.
Plan to share individual participant data: YES
IPD sharing description: After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement. Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
IPD time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
IPD access criteria: For study documents - upon signing of a 'Document Sharing Agreement'.For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Clinical trial NCT04381169: Aggressive Versus Non-aggressive Goal-directed Fluid Resuscitation in Acute Pancreatitis
Official title: Effect of Early Weight-based Aggressive Versus Non-aggressive Goal-directed Fluid Resuscitation in the Early Phase of Acute Pancreatitis: an Open-label Multicenter Randomized-controlled Trial
Acronym: WATERFALL
Sponsor: Hospital General Universitario de Alicante (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Increased frequency of fluid overload on the aggressive fluid resuscitation arm of treatment
Enrollment: 249.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-28
Primary completion date: 2021-09-25
Completion date: 2021-09-25
Plan to share individual participant data: NO
Clinical trial NCT05069935: FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Official title: A Phase I, Open-Label, Multicenter Study of FT538 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Sponsor: Fate Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: This study was terminated by the Sponsor.
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-15
Primary completion date: 2023-08-11
Completion date: 2023-08-11
Plan to share individual participant data: NO